CN Patent

CN101198316A — 纳米微粒双膦酸盐组合物

Assigned to Perrigo Pharma International DAC · Expires 2008-06-11 · 18y expired

What this patent protects

描述了有效平均粒径小于2000nm的纳米微粒双膦酸盐组合物。该组合物在治疗哺乳动物骨吸收中是有用的。

USPTO Abstract

描述了有效平均粒径小于2000nm的纳米微粒双膦酸盐组合物。该组合物在治疗哺乳动物骨吸收中是有用的。

Drugs covered by this patent

risedronate-sodium (RISEDRONATE SODIUM)

Patent Metadata

Patent number: CN101198316A
Jurisdiction: CN
Classification: —
Expires: 2008-06-11
Drug substance claim: No
Drug product claim: No
Assignee: Perrigo Pharma International DAC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.